Dr Anna Calkin

Dr Anna Calkin is a National Heart Foundation Future Leader Fellow and Head of the Lipid Metabolism and Cardiometabolic Disease Laboratory at the Baker Heart & Diabetes Institute. She has developed a research program that focuses on preventing the onset of cardiometabolic diseases driven by excess lipid accumulation, including obesity and diabetes-associated cardiomyopathy, atherosclerosis, hepatic steatosis and skeletal muscle and liver insulin resistance. In addition, she has an interest in identifying novel regulators of lipid metabolism using a novel discovery platform she has established with several collaborators, which combines cutting edge proteomics and lipidomics across 100+ strains of genetically diverse inbred mice. This has led to the identification of many novel and exciting targets. Prior to this, Anna undertook post-doctoral studies at UCLA where she defined the E3 ligase, IDOL, as an evolutionarily conserved mechanism for the regulation of lipid metabolism. She demonstrated its importance in regulating cholesterol levels in humans and developed a novel mouse model of atherosclerosis, currently available from Jackson Laboratories.